Drug Trial Radar · NCT03809221
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation
Last checked: Nov 19, 2026Latest source record: Jan 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,892
Planned (sponsor's estimate)
Start
Feb 1, 2019
Primary completion
Sep 1, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Peking University People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- West China Hospital; Peking University First Hospital; The First Affiliated Hospital of Zhengzhou University; Henan Provincial People's Hospital; The Second Hospital of Hebei Medical University; First Affiliated Hospital of Wenzhou Medical University; Jiangxi Maternal and Child Health Hospital; Second Affiliated Hospital of Wenzhou Medical University; Second Affiliated Hospital of Zhengzhou University; Shanxi Provincial Maternity and Children's Hospital; First Affiliated Hospital of Guangxi Medical University; Guangxi Maternal and Child Health Hospital; Yinchuan Municipal Maternal and Child Health Hospital; Xinjiang Jiayin Hospital
- First posted
- Jan 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Since the first "tube baby", Louise Brown, was born in the United Kingdom in 1978, many infertile couples have been benefitted from in vitro fertilization and embryo transfer (IVF-ET) and intracytoplasmic sperm injection (ICSI). Although a late starter, China is developing rapidly in ART and playing a more and more important role in the area of reproductive medicine. In spite of the continuous development in ART, so far, the overall success rate of IVF/ICSI is still hovering around 25-40%. There are many factors influencing the success rate of IVF/ICSI. Among them, an appropriate controlled ovarian hyperstimulation (COH) protocol is directly associated with the number of oocyte retrieved, as well as the number and quality of embryos, which exert an important influence on the success rate of IVF/ICSI. The luteal phase pituitary down-regulation protocol is one of the most widely used COH protocols in clinical practice, particularly in China. Though effective, it may lead to an increased incidence of ovarian hyperstimulation syndrome (OHSS), as well as a negative impact on endometrial receptivity. The coping strategy is to freeze all the embryos and transfer in the next cycle. Though avoiding the above mentioned adverse effects, such strategy increases the time to pregnancy (TTP) and therefore results in certain psychological and economic burdens for infertile couples. In recent years, some Chinese researches applied the early follicular full-dose down-regulation protocol that is always performed to women with endometriosis to a more general IVF/ICSI population and found a clinical pregnancy rate of 64% in the fresh embryo transfer cycle, much higher than that of the luteal phase down-regulation protocol. Furthermore, since this protocol decrease the risk of progesterone elevation on hCG day, it increases the fresh embryo transfer rate and shortens TTP. Given most studies regarding the effectiveness and safety of the early follicular phase full-dose down-regulation protocol are retrospective studies, the results may be biased by several confounding factors. Therefore, we would like to conduct a multicenter, randomized controlled trial to compare the pregnancy outcome and safety indicators between the early follicular phase full-dose down-regulation protocol and the luteal phase down-regulation protocol.
Conditions
- Infertility, Female
Interventions
Triptorelin acetateDrug
Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- live birth rate per transferred cycleTime frame: 28 weeks of gestation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.